A review of NHS England's Infusions and Special Medicines Programme achievements and learning for ensuring sufficient capacity and resilience in the provision of aseptic medicines for NHS patients, focusing on considerations for future strategy.

Since the national aseptics review in 2020, NHS England's Infusions and Special Medicines Programme has been been working on the recommendations to ensure sufficient capacity and resilience in the provision of aseptic medicines for NHS patients. 
Now, more than five years since the review, is it time for a strategic rethink?

• Outcomes, achievements and learning from the Infusions and Special Medicines Programme so far - aseptic production hubs, standardisation, workforce etc.
• Changes in the strategic landscape - drivers and risks
• Benefits and risks in the make vs. buy decisions for aseptic medicines
• Future strategic options for ensuring aseptic production will meet patient needs over the next five years.